Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions

Brian J. Miller, David R. Goldsmith

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

The evidence to date, coupled with advances in immunology and genetics has afforded the field an unparalleled opportunity to investigate the hypothesis that a subset of patients with schizophrenia may manifest an immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, alleviate symptoms, and improve quality of life in both at-risk populations and patients with established schizophrenia. In this paper, we will first summarize the findings on immune dysfunction in schizophrenia, including (1) genetic, prenatal, and premorbid immune risk factors and (2) immune markers across the clinical course of the disorder, including cytokines; C-reactive protein; immune cells; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imaging of neuroinflammation; infections; and clinical trials of anti-inflammatory agents and immunotherapy. We will then discuss a potential mechanistic framework toward increased understanding of a potential schizophrenia immunophenotype. We will then critically appraise the existing literature, and discuss suggestions for the future research agenda in this area that are needed to rigorously evaluate this hypothesis.

Original languageEnglish (US)
Pages (from-to)299-317
Number of pages19
JournalNeuropsychopharmacology
Volume42
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Schizophrenia
Immunologic Factors
Allergy and Immunology
C-Reactive Protein
Autoantibodies
Immunotherapy
Oxidative Stress
Anti-Inflammatory Agents
Biomarkers
Quality of Life
Clinical Trials
Cytokines
Direction compound
Antibodies
Infection
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Towards an Immunophenotype of Schizophrenia : Progress, Potential Mechanisms, and Future Directions. / Miller, Brian J.; Goldsmith, David R.

In: Neuropsychopharmacology, Vol. 42, No. 1, 01.01.2017, p. 299-317.

Research output: Contribution to journalReview article

@article{5c631bff71b64f04a3e805bd0acd321a,
title = "Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions",
abstract = "The evidence to date, coupled with advances in immunology and genetics has afforded the field an unparalleled opportunity to investigate the hypothesis that a subset of patients with schizophrenia may manifest an immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, alleviate symptoms, and improve quality of life in both at-risk populations and patients with established schizophrenia. In this paper, we will first summarize the findings on immune dysfunction in schizophrenia, including (1) genetic, prenatal, and premorbid immune risk factors and (2) immune markers across the clinical course of the disorder, including cytokines; C-reactive protein; immune cells; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imaging of neuroinflammation; infections; and clinical trials of anti-inflammatory agents and immunotherapy. We will then discuss a potential mechanistic framework toward increased understanding of a potential schizophrenia immunophenotype. We will then critically appraise the existing literature, and discuss suggestions for the future research agenda in this area that are needed to rigorously evaluate this hypothesis.",
author = "Miller, {Brian J.} and Goldsmith, {David R.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/npp.2016.211",
language = "English (US)",
volume = "42",
pages = "299--317",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Towards an Immunophenotype of Schizophrenia

T2 - Progress, Potential Mechanisms, and Future Directions

AU - Miller, Brian J.

AU - Goldsmith, David R.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The evidence to date, coupled with advances in immunology and genetics has afforded the field an unparalleled opportunity to investigate the hypothesis that a subset of patients with schizophrenia may manifest an immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, alleviate symptoms, and improve quality of life in both at-risk populations and patients with established schizophrenia. In this paper, we will first summarize the findings on immune dysfunction in schizophrenia, including (1) genetic, prenatal, and premorbid immune risk factors and (2) immune markers across the clinical course of the disorder, including cytokines; C-reactive protein; immune cells; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imaging of neuroinflammation; infections; and clinical trials of anti-inflammatory agents and immunotherapy. We will then discuss a potential mechanistic framework toward increased understanding of a potential schizophrenia immunophenotype. We will then critically appraise the existing literature, and discuss suggestions for the future research agenda in this area that are needed to rigorously evaluate this hypothesis.

AB - The evidence to date, coupled with advances in immunology and genetics has afforded the field an unparalleled opportunity to investigate the hypothesis that a subset of patients with schizophrenia may manifest an immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, alleviate symptoms, and improve quality of life in both at-risk populations and patients with established schizophrenia. In this paper, we will first summarize the findings on immune dysfunction in schizophrenia, including (1) genetic, prenatal, and premorbid immune risk factors and (2) immune markers across the clinical course of the disorder, including cytokines; C-reactive protein; immune cells; antibodies, autoantibodies and comorbid autoimmune disorders; complement; oxidative stress; imaging of neuroinflammation; infections; and clinical trials of anti-inflammatory agents and immunotherapy. We will then discuss a potential mechanistic framework toward increased understanding of a potential schizophrenia immunophenotype. We will then critically appraise the existing literature, and discuss suggestions for the future research agenda in this area that are needed to rigorously evaluate this hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=84991641369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991641369&partnerID=8YFLogxK

U2 - 10.1038/npp.2016.211

DO - 10.1038/npp.2016.211

M3 - Review article

C2 - 27654215

AN - SCOPUS:84991641369

VL - 42

SP - 299

EP - 317

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -